Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Chord Energy has added 9.2% this week to $154.56, and the most interesting development is not the price move itself but what happened on the Street the same day: Scotiabank initiated coverage at Sector Outperform with a $192 target, arriving just hours after Morgan Stanley raised its own target to $178 from $169.
The analyst picture has sharpened considerably since the note published four days ago. At that point targets were clustering in a $174 to $195 range and the mean sat at $176. That picture now has more conviction behind it. Scotiabank's $192 entry and Morgan Stanley's lift both sit well above Thursday's close, and Truist's $195 Buy from earlier in the week remains the high on the Street. The constructive majority is offset by two hold-rated voices: Jefferies at $150 and Citi at $150, both now a full 3% below the current price. The consensus remains Buy, and with the stock still trading at a near-10% discount to the mean target, the Street's directional read is intact even after this week's rally. At 3.4x EV/EBITDA and 0.91x book, valuation remains undemanding. The EPS momentum factor score leads the fundamental rankings at 87th percentile over 30 days, though the forward earnings picture is softer: the 12-month forward year-on-year growth score sits at just the 26th percentile, a reminder that consensus does not yet expect a sharp ramp in earnings.
Short positioning pulls in the opposite direction. Short interest climbed 8.3% over the past seven days to 7.0% of the free float, continuing the rebuild noted in the previous article, and is up 27.9% over the past month. That is a meaningful and sustained build, not noise. Yet the borrowing market offers no amplifier: cost to borrow has actually eased 17% on the week to 0.38%, and availability is extremely loose at 1,584%, meaning there are roughly sixteen shares available to borrow for every one already lent out. There is no squeeze mechanic visible in the lending data. Options tell a different story again: the put/call ratio has dropped to 0.53, more than two standard deviations below its 20-day average of 0.61. That is a notably call-skewed reading for a stock with shorts rebuilding, suggesting options traders are positioning for further upside rather than hedging against a reversal.
The insider register adds a note of caution. Over the past 90 days, insiders net sold approximately 47,673 shares worth roughly $6.9 million, all of it in open-market transactions with no 10b5-1 plan disclosed. CEO Daniel Brown sold around $1.6 million of stock in late August near $150 to $152, which is close to where the stock is trading now. Director Samantha McKinney also sold in September at similar prices. None of these were pre-planned sales, which gives them more weight than routine plan-driven distributions, though the amounts are modest relative to position sizes. BlackRock holds 12.9% and remains the largest institutional holder, with State Street and Dimensional both adding shares in the most recent reported quarter. No 13D activist is on the register.
Chord reports on November 4, seventeen days away. The stock has moved modestly on recent prints: up 1.1% the day after the August 2026 report, and down about 3.2% on the prior quarter. The setup heading into that date is a stock that has re-rated 9% in a week with fresh sell-side support, a short base that is building but cheaply and easily borrowed, and options traders leaning bullish. The gap between where insiders were selling in August and where the stock now trades is the tension worth watching into the print.
See the live data behind this article on ORTEX.
Open CHRD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
